Prev Close | 21.00 |
Day Low/High | 20.24 / 21.29 |
52 Wk Low/High | 1.71 / 30.17 |
Prev Close | 21.00 |
Day Low/High | 20.24 / 21.29 |
52 Wk Low/High | 1.71 / 30.17 |
Exchange | NASDAQ |
Shares Outstanding | 39.61B |
Market Cap | 831.91M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
However, utilities and some technology names bucked the trend.
Own them, or take something off the table?
Try to find bullish charts that don't all look the same.
I'm content to sit in cash and wait for a trigger.
The S&P is putting up strong resistance that has withstood several attacks today.
In other words, don't overstay your welcome.
This action makes it a good time to add to two quality names.
Qualcomm seems to be breaking out of a bullish flag, and Celldex has a fantastic chart.
I'm content to head into the weekend with my short-term book mostly on the cash side.
Blackberry's Flying Circus, Foolish Filmmaker, Celldex Shenanigans, Benmosche's Big Mouth and Chrysler's Conundrum highlight Gregg Greenberg's list of dumb things on Wall Street this week.
Favorable charts for Celldex, Repligen and Arrowhead Research.
Maintain a long-side bias until composure changes.
The S&P is in an uptrend but the market is in digestion mode.
The best thing to do is get out of the way and let it play out.
And the close put an exclamation point on it.
There's still speculative interest out there.
It really is amazing how this market keeps roaring back.
I'm eager to enter new trades but leery of forcing things.
Action is a mixed bag so far.
Adam Feuerstein, Sr. Columnist for TheStreet, says Celldex Therapeutics is the next big thing in biotech.
Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.
Adam Feuerstein, senior columnist, explains why the BIO CEO Conference is the next big thing in biotech.